HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270007308616v1 47/12/1540    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahmood, I. Articles by Green, M. D. Search for Related Content PubMed PubMed Citation Articles by Mahmood, I. Articles by Green, M. D. Social Bookmarking                   What's this?

Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies

From the Office of Blood Review & Research (OBRR) (Dr Mahmood) and Office of Vaccine Review & Research (OVRR) (Dr Green), Center for Biologic Evaluation and Research, Food & Drug Administration (FDA), Rockville, Maryland (Dr Mahmood).

Drug interactions can alter the pharmacokinetics and/or pharmacodynamics of a drug. In pharmacokinetic drug interactions, the concentrations of 1 or more drugs are altered by another. This change in concentration in a given drug may be due to changes in absorption, distribution, metabolism, or elimination. The pharmacodynamic interaction can lead to additive, synergistic, or antagonistic effects of a drug. Drug interaction studies are regularly conducted with conventional drugs (small molecules), but very few drug interaction studies have been performed with macromolecules (therapeutic proteins or monoclonal antibodies). This is mainly because most macromolecules are not metabolized by the cytochrome P450 system, and their mechanism of elimination is complex. However, it has been shown in several studies that interferons can have an impact on the cytochrome P450 system that may alter the pharmacokinetics and pharmacodynamics of a conventional drug when given with interferons. Therefore, it is important to evaluate the effect of other classes of macromolecules (cytokines, interleukins, monoclonal antibodies) on drug-metabolizing enzymes. It is also imperative that the effects of conventional drugs on the pharmacokinetics and pharmacodynamics of macromolecules be conducted. The present review encompasses several drug interaction studies that were conducted with macromolecules and highlights the impact of these studies on the pharmacokinetics and/or pharmacodynamics of the involved drugs.

Key Words: Drug interaction • therapeutic proteins • monoclonal antibodies

Address for correspondence: Iftekhar Mahmood, PhD, Office of Blood Review & Research (OBRR), Center for Biologic Evaluation and Research, Food & Drug Administration, 1451 Rockville Pike, Rockville, MD 20850; e-mail: Iftekhar.mahmood{at}fda.hhs.gov.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Panayotatos Drug-binding Cavities in Long-Lived Biologics: Cause for Concern but Also Potential Benefit J. Clin. Pharmacol., October 1, 2008; 48(10): 1208 - 1211. [Abstract] [Full Text] [PDF]